Emulate Closes $82 Million Series E Financing to Scale Amid Rapid Growth in Organ-on-a-Chip Market

Emulate, Inc., a leading provider of next generation in vitro models, today announced the close of an $82 million Series E financing round led by existing investor Northpond Ventures with additional participation from Perceptive Advisors. With this investment, Emulate has raised nearly $225 million to date.

“This fundraise is a testament to the fact that Emulate organ-chips are allowing the exploration of human biology like never before,” said Jim Corbett, CEO of Emulate. “Over the last year, we have bolstered our leadership team, accelerated product development goals, and seen healthy growth in demand for our products. Several leading indicators validate our belief that organ-on-a-chip technology will dramatically transform the entire drug discovery and development pipeline and ultimately eliminate unnecessary animal testing.”

Emulate develops and manufactures next-generation in vitro models that enable researchers to replicate and study human biology and disease, helping them understand and predict drug response with greater precision and detail than possible with conventional cell culture or animal-based methods. Organ-on-a-chip technology by Emulate provides flexible microenvironments containing tiny hollow channels lined with living cells and tissues that can be subjected to mechanical forces that mirror breathing or digestion in the human body. The technology is used by leading academic researchers, government entities, and many of the largest pharmaceutical companies to better understand the biology of human disease.

“We believe Emulate’s transformative technology is poised to accelerate innovation in the drug discovery and development process,” said Sharon Kedar, CFA, Co-Founder and Partner at Northpond Ventures. “Our ongoing investment in Emulate reflects our confidence that organ-on-a-chip technology will be a key solution for preclinical testing of therapeutic compounds.”

The funds raised through the Series E financing round will support a significant scale-up in research and development activities to facilitate the creation of new human-relevant organ-on-a-chip models in immunology, neuroinflammation, tumor modeling, and more. To help meet growing global demand, Emulate is extending operations in the Asia Pacific region with two new distributors.

“With biomedical research and pharmaceutical industries focused on leveraging the human immune system in the development of new biologic medicines, immunotherapies, and vaccines, human-relevant modeling methods are clearly essential to the success of development programs designed to improve human health,” said Sam Chawla, Portfolio Manager at Perceptive. “The rapid growth in the adoption of Emulate organ-chip technology is a testament to the value they can provide to researchers seeking to understand the mechanisms of disease and treatment options.”

Recently in the United States, the FDA Modernization Act and the Humane Research Act have been introduced in Congress calling on the support for alternatives to animal testing, citing scientific inadequacies and ethical concerns associated with animal models.

SourceEmulate
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy